Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Consolidated Net Income fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Consolidated Net Income of -$54.9 million as of Q3 2025, which was down 9.03% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Consolidated Net Income ranged from a high of -$24.9 million in Q2 2023 and a low of -$111.3 million during Q4 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Consolidated Net Income averaged around -$47.1 million, with its median value being -$42.6 million (2024).
  • Per our database at Business Quant, Centessa Pharmaceuticals' Consolidated Net Income skyrocketed by 61.51% in 2023 and then crashed by 202.22% in 2024.
  • Centessa Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$43.2 million in 2022, then rose by 14.68% to -$36.8 million in 2023, then slumped by 202.22% to -$111.3 million in 2024, then dropped by 28.96% to -$54.9 million in 2025.
  • Its last three reported values are -$54.9 million in Q3 2025, -$50.3 million for Q2 2025, and -$26.1 million during Q1 2025.